Innovation and Biomarkers in Cancer Drug Development Meeting (November 29-30, 2018; Brussels, Belgium)

The Innovation and Biomarkers in Cancer Drug Development meeting will convene November 29-30, 2018 in Brussels, Belgium and will highlight cooperative approaches to cancer drug development with new cancer biomarkers. This meeting is a collaboration between the European Organisation for Research and Treatment of Cancer (EORTC), NCI, the European Medicines Agency (EMA), and the American Association for Cancer Research (AACR). Registration is open from May 17, 2018 - November 15, 2018.

Several DCTD staff have been involved in the planning and implementation of this conference, including the following:

Lyndsay Harris, MD, Cancer Diagnosis Program
Organizing Committee
Speaker: NCI-MATCH Trial: Lessons Learned

Tracy Lively, PhD, Cancer Diagnosis Program
Organizing Committee
Session Chair: Challenges of Clinical Trial Design: New Perspectives

Nina Lukinova, PhD, Cancer Diagnosis Program
Scientific Committee

Helen Moore, PhD, Cancer Diagnosis Program
Scientific Committee

Malcolm Smith, MD, PhD, Cancer Therapy Evaluation Program
Scientific Committee

Laura Yee, PhD, Biometric Research Program
Scientific Committee

The meeting can be followed on Twitter at #IBCD2018.